LGC Standards Partners with PRIMACYT to Improve Access to Hepatocytes for Drug Discovery Research
News Feb 20, 2011
LGC Standards has announced the addition of the PRIMACYT range of in-vitro products and services to its portfolio of life science research and drug discovery products. PRIMACYT currently offers hepatocyte cells to the drug discovery research community throughout Europe.
The drug development community recognizes the need for improved in-vitro modelling systems and the collaboration between LGC - which holds the designated role as the UK's National Measurement Institute for chemical and bioanalytical measurement - and highly innovative companies such as PRIMACYT provides an ideal platform from which to develop new and more effective in-vitro systems and to facilitate their distribution.
Elizabeth Jordain, Managing Director of LGC Standards commented: “We are delighted to add the PRIMACYT in-vitro products and services to our drug discovery products and services portfolio. The application and development of improved in-vitro systems as predictors of in-vivo response is a key area of focus for our ADMETox business and we believe the partnership with PRIMACYT creates an ideal opportunity for our two companies to work together to develop improved systems for in-vitro analysis. We expect that the PRIMACYT collaboration will offer opportunities to expand both the range of products available in the PRIMACYT portfolio and to develop new distribution channels for these important model systems for the drug discovery and development community.”
Dieter Runge, Managing Director at PRIMACYT said, “We have seen significant increase in the demand for fresh hepatocytes to support in-vitro research and our partnership with LGC Standards offers an ideal platform from which to implement our product development and expanded distribution initiatives.”
Tuberculosis (TB), an ancient and notoriously difficult disease to treat, has killed millions through the course of human history; and the antibiotics that have been used to fight the disease in recent history are becoming less and less effective. In the face of this reality, researcher Prof. Dennis Wright has improved upon a new way to thwart the tricky pathogen, mycobacterium tuberculosis.READ MORE
Researchers have solved the structures of the cancer-promoting enzymes USP25 and USP28, and identified significant differences in their activities. This knowledge provides the molecular basis for the development of new and highly specific anti-cancer drugs, with a low risk of side-effects.READ MORE